Research Article
Nomogram Based on microRNA Signature Contributes to Improve Survival Prediction of Clear Cell Renal Cell Carcinoma
Table 2
Baseline demographic and clinical characteristics of the included patients with clear cell renal cell carcinoma.
| | Development cohort () | Validation cohort () | value |
| | Age () | | | 0.5099 | | Sex (, %) | | | 0.02493 | | Male | 152 (60.32) | 176 (69.84) | | | Female | 100 (39.68) | 76 (30.16) | | | AJCC stage (, %) | | | 0.7451 | | I | 123 (48.81) | 125 (49.60) | | | II | 23 (9.13) | 29 (11.51) | | | III | 65 (25.79) | 57 (22.62) | | | IV | 41 (16.27) | 41 (16.27) | | | Grade (, %) | | | 0.1368 | | I | 3 (1.19) | 10 (3.97) | | | II | 102 (40.48) | 113 (44.84) | | | III | 107 (42.46) | 95 (37.70) | | | IV | 40 (15.87) | 34 (13.49) | | | Laterality (, %) | | | 1 | | Left | 117 (46.43) | 117 (46.43) | | | Right | 135 (53.57) | 135 (53.57) | | | Risk score () | | | 0.8244 | | Survival months () | | | 0.9696 | | Survival status (, %) | | | 0.57161 | | Dead | 82 (32.54) | 88 (34.92) | | | Alive | 170 (67.46) | 164 (65.08) | |
|
|
SD: Standard Deviation; AJCC: American Joint Committee on Cancer.
|
